Results 21 to 30 of about 35,838 (264)

Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer

Cancer Science
The global phase 3 DESTINY‐Breast03 study (ClinicalTrials.gov; NCT03529110) showed statistically significant and clinically meaningful improvements in progression‐free survival (PFS) and overall survival (OS) with trastuzumab deruxtecan (T‐DXd) over ...
Hiroji Iwata, Binghe Xu, Sung-Bae Kim, Wei-Pang Chung, Y. Park, Min Hwan Kim, Ling-Ming Tseng, Chi-Feng Chung, Chiun-Sheng Huang, Jeehyun Kim, Joanne W Y Chiu, T. Yamashita, Wei Li, A. Egorov, Soichiro Nishijima, Shunsuke Nakatani, Yuji Nishiyama, M. Sugihara, J. Cortes, Seock-Ah Im   +19 more
semanticscholar   +3 more sources

Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?

Liječnički vjesnik, 2023
Breast cancer that overexpresses the human epidermal growth factor receptor 2 (HER2) is considered to be HER2-positive. The novel HER2- directed antibody drug conjugate, trastuzumab deruxtecan (T-DXd), is formed by covalently joining the monoclonal ...
Džana Bjelić, Sara Bognar, Jelena Benčić, Manuela Bajan, Natalija Dedić Plavetić   +4 more
doaj   +1 more source

Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer [PDF]

Therapeutic Advances in Medical Oncology, 2021
Trastuzumab deruxtecan (T-DXd) is a novel anti-human epidermal growth factor receptor 2 (HER2) antibody–drug conjugate composed of a monoclonal anti-HER2 antibody and a topoisomerase I inhibitor, DX-8951 derivative (an exatecan derivative). T-DXd showed potential anti-tumor activities in HER2-positive gastric cancer cell lines and xenograft models. In
Daisuke Kotani, Kohei Shitara
openaire   +4 more sources

Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond [PDF]

Expert Opinion on Biological Therapy, 2021
Despite the substantial improvements made in human epidermal growth factor receptor 2 (HER2)-targeted therapies since the approval of trastuzumab more than 20 years ago, there is still considerable unmet need in patients with HER2-expressing breast cancer (BC) and other solid tumors.
Perez, Jose, Garrigós, Laia, Gion, Maria, Jänne, Pasi A, Shitara, Kohei, Siena, Salvatore, Cortés, Javier   +6 more
openaire   +3 more sources

Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review

Опухоли женской репродуктивной системы, 2023
The review gives the definition of HER2-low status, shows its clinical and biological role in patients with advanced breast cancer. A unique mechanism of action of trastuzumab deruxtecan and potential for its use in advanced breast cancer with HER2-low ...
I. V. Kolyadina
doaj   +1 more source

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors [PDF]

International Journal of Molecular Sciences, 2021
HER2 targeted therapies have significantly improved prognosis of HER2-positive breast and gastric cancer. HER2 overexpression and mutation is the pathogenic driver in non-small cell lung cancer (NSCLC) and colorectal cancer, however, to date, there are no approved HER2-targeted therapies with these indications. Trastuzumab deruxtecan (T-DXd) is a novel
Indini A., Rijavec E., Grossi F.
openaire   +3 more sources

Trastuzumab Deruxtecan for HER2+ Advanced Breast Cancer

Future Oncology, 2021
Trastuzumab deruxtecan (T-DXd, DS-8201), an anti-HER2 antibody-drug conjugate, has shown significant clinical benefits in HER2+ metastatic breast cancer patients. In the phase 2 DESTINY-Breast01 trial, T-DXd demonstrated an objective response of 60.9% and median progression-free survival of 16.4 months, laying the foundation for accelerated approval in
Jiyun Lee, Yeon Hee Park
openaire   +7 more sources

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

Breast, 2023
Background: Patients with HER2+ breast cancer (BC) frequently develop leptomeningeal metastases (LM). While HER2-targeted therapies have demonstrated efficacy in the neoadjuvant, adjuvant, and metastatic settings, including for parenchymal brain ...
Anna-Maria Lazaratos, Sarah M. Maritan, Andrea Quaiattini, Amelie Darlix, Ivica Ratosa, Emanuela Ferraro, Gaia Griguolo, Valentina Guarneri, Alessia Pellerino, Silvia Hofer, William Jacot, Hans-Joachim Stemmler, Marcel P.H. van den Broek, Nika Dobnikar, Francois Panet, Zubin Lahijanian, Aki Morikawa, Andrew D. Seidman, Riccardo Soffietti, Lawrence Panasci, Kevin Petrecca, April A.N. Rose, Nathaniel Bouganim, Matthew Dankner   +23 more
doaj   +1 more source

Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis

Frontiers in Oncology, 2023
IntroductionMany systemic treatment options are available for patients with human epidermal growth factor 2 (HER2)-positive breast cancer brain metastases.
Xingfa Huo, Xingfa Huo, Guoshuang Shen, Tianzhuo Wang, Jinming Li, Qiqi Xie, Zhen Liu, Miaozhou Wang, Fuxing Zhao, Dengfeng Ren, Jiuda Zhao   +10 more
doaj   +1 more source

Safety of trastuzumab deruxtecan: A meta‐analysis and pharmacovigilance study

Journal of Clinical Pharmacy and Therapeutics, 2022
This study aimed to explore the safety profile of trastuzumab deruxtecan (T-DXd, formerly DS-8201a) using multi-source medical data.We explored trastuzumab deruxtecan related adverse events (AEs) in clinical trials available in ClinicalTrials.gov and electronic databases (MEDLINE, EMBASE and PubMed) up to July 16, 2022.
Zihan Guo, Yunlan Ding, Mengmeng Wang, Jiyong Liu, Qing Zhai, Qiong Du   +5 more
openaire   +2 more sources